Article
Glaucoma combo solution earns preliminary approval
The FDA has issued an approvable letter for the fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution (Extravan) for the treatment of glaucoma, according to Alcon Laboratories, its manufacturer.
The FDA has issued an approvable letter for the fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution (Extravan) for the treatment of glaucoma, according to Alcon Laboratories, its manufacturer.
The company said it would meet with the FDA to clarify what steps are yet required to gain final marketing approval.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
